Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience-Reference-Cited by-同舟云学术

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience

Published:2011-11 Issue:11 Volume:35 Page:1444-1448
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Le Bras Fabien,Sebert Marie,Kelaidi Charikleia,Lamy Thierry,Dreyfus François,Delaunay Jacques,Banos Anne,Blanc Michel,Vey Norbert,Schmidt Aline,Visanica Sorin,Eclache Virginie,Turlure Pascal,Beyne-Rauzy Odile,Guerci Agnès,Delmer Alain,de Botton Stéphane,Rea Delphine,Fenaux Pierre,Adès Lionel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference13 articles.

1. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

2. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients;Haase;Blood,2007

3. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31;Giagounidis;Leukemia,2004

4. The 5q- syndrome;Giagounidis;Hematology,2004

5. 5q-, twenty-five years later: a synopsis;Van den Berghe;Cancer Genet Cytogenet,1997

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11);International Journal of Hematology;2023-12-13

2. Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity;BLOOD RESEARCH;2021-06-30

3. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations;Blood Reviews;2019-03

4. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs;Cardiovascular & Hematological Disorders-Drug Targets;2019-01-28

5. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis;Clinical Lymphoma Myeloma and Leukemia;2018-08